Buy Online Fragment 176-191 | Peptide Research & Sciences
HGH Frag 176-191, growth hormone fragment 176-191, or simply fragment 176-191 is a commercially synthesized hormone that is a cleavage of the natural human growth hormone produced by the pea-sized organ at the base of the brain. It is a version of the natural peptide but is cleaved from the 176 to 191 amino acids.
The identification of fragment 176-191 is credited to researchers from Monash University who discovered that the most active part of the peptide is between amino acid numbers 176 to 191. The fragment has the ability to induce the breakdown of lipids in a process called lipolysis. The active region is less than 10% of the entire human growth hormone peptide.
However, it is imperative to understand that fragment 176-191 does not have any effect on the level of insulin or insulin resistance. The principle of action of the peptide is through mimicking the natural activity of growth hormone and recent studies revealed that the peptide possesses lipid breaking and fat regulation properties. In addition, it also helps block the deposition of fats on visceral and peripheral organs.
Read More »
A Brief History of Fragment 176-191
The fragment is a biomolecular peptide that has structural and configurationally similarity to the growth hormone releasing hormone. The peptide has shown enhanced ability to induce the production and the secretion of growth hormone from the pituitary gland.
The somatotropes are small cells that are important in the production and release of growth hormone from the pituitary gland to the target organ where it exerts its functions. One of the most important facts that we need to understand is that the production of growth hormone is in tandem with that of somatostatin. Therefore, hormone production should be enhanced for optimal functionality.
The formation of a peptide occurs when the N-terminal and the carboxyl terminal are combined and the peptide is essential in reducing the formation and deposition of fats on peripheral organs. Inhibiting the conversion of glucose to glycogen and other fat components for deposit when the fats are stored and energy consumption is low, then it is a problem because obesity may arise. Fragment 176-191 works through the blocking and killing of blood vessels which supply the fat cells or adipocytes. Therefore, they die off.
Frag 176-191 Structure
Studies indicated that fragment 176-191 is important in increasing the ability of the research organism to burn fats. The peptide does this by inhibiting the conversion of glucose to glycogen which is usually stored in peripheral organs.
The ability to induce reduction of fats in visceral and peripheral organs can be attributed to the structure of the peptide. Fragment 176-191 has been designed to tackle adipocytes formation because it has a short and very active molecule which initiates the fats burning process.
Because of this unique structure, the peptide has shown the ability to enhance lipolysis or the burning of excess fats from peripheral organs 12.5 times more than the natural growth hormone.
Since fragment 176-191 mimics the activity of the natural occurring growth hormone, research showed that when the peptide is administered to the research organism, there is a significant weight reduction. One of the main contributors of fats or increased weight in test organisms is impaired glucose absorption or the burning of fats is impaired.
When applying fragment 176-191 to the test organism, it has shown to be effective in enhancing the multiplication of fat cells. Current research on the peptide showed that when it is administered in the right dosage, the peptide could reduce the aging process.
One-week-old mice were injected with the peptide and the results obtained indicated that the peptide has the potential of being used in further research and development. The condition of conducting the study was based on food intake of the mice, their age, cellular multiplication and signs of aging among the mice under study.
Fragment 176-191 is often sold in kits and its application on test animal subjects should be done at least seven days per week to ensure consistency in the research. Researchers recommend that the peptide be administered before feeding the test organism or the planned exercise.
The peptide acts via biological mechanism and it evokes a desired reaction through the mimicry of the natural production of the growth hormone. Fragment 176-191 is supplied in vials of white lyophilized or a freeze-dried powder.
It is important to note that the peptide should be sterile. The aqueous soluble solution should be available for your study. It is imperative that you reconstitute the peptide only when you need it and not reconstitute the whole vial and then refrigerate it. Always follow the instructions on the kit when reconstituting the vial.
The conditions should be sterile to avoid any contamination of the peptide. Moreover, you should store fragment 176-191 at 2-8 degree Celsius. When reconstituting for research, remove the vial to thaw at room temperature. Increasing the temperature rapidly will disintegrate the peptide bonds.
Mechanism of Action
fragment 176-191 mechanism of action is through the blockage of cells which supply energy and nutrition to the cells when the nutrition is cut off the cells are denatured, they lose their activity and viability, therefore, they die off.
When the cells die off, they are secreted through the mitochondrial mechanism. It is vital to note that when there is a constant death of cells, it may result in fat loss and weight loss as well. According to recent research, when fragment 176-191 was administered to the test subjects, it reduced their serum glucose plasma and insulin levels. Moreover, the peptide can act in synergy with other fragments such as fragment 178-191, 172-191 and 178-191.
The functionality of fragment 176-191 largely depends on the lead sequence or what is commonly referred to as informational sequence. The sequence must be present in the right configuration and the right conformation for it to exert any activity.
This is the most important part of the peptide because it increases the affinity of the peptide and the binding of proteases. In addition, the area is rich in amino acids such as proline and changes in the conformation of fragment 176-191 could result in cytoplasmic domain band 3 on the red blood cell membranes to change its conformation.
A conformational change is an important aspect because it is vital in enhancing the lipolytic activity of fragment 176-191. This has no effect on the level of glucose in the serum. The mechanism of action is through the mimicry of the growth hormone.
Recent research indicated that fragment 176-191 does not induce hyperglycemia or an increase in the levels of glucose in serum. It does not compete with human growth hormone for receptors. The peptide has a positive feedback mechanism in the prevention of lipodystrophy.
The fragment has the ability to induce fat oxidation and increase in energy consumption through the generation of muscle cells and fat oxidation. The synergistic action of the GH with the fragment is essential in increasing the level of growth hormone through activation of the somatotrophic cells on the pituitary gland.
Role of HGH Frag 176-191 in Fat Reduction
Studies have shown that the application of fragment 176-191 is important in removing stubborn fat in the adipose tissues. This is important in increasing muscle mass when the fats are oxidized. Findings from research showed that fragment 176-191 can be used in the reduction of lipolysis.
However, this is still under research because the peptides have not been approved for human consumption. The fragment is thirteen times more potent in stimulating lipolysis than any other peptide in its category. Expected side effects are minimal and the peptide has proven to be crucial in accentuating the effects, potency and its effectiveness is still under research.
The analysis and research is more focused on the ability to use the peptide in treating adverse conditions that are often associated with excess fast. In the modern world, you will be able to get vials of different peptides to use in research and other studies.
The peptides are usually supplied in freeze-dried or powder form and they are to be used for research purposes only. When using fragment 176-191, store it at room temperature for 60 days and 30 days in 2-8 degree Celsius.
Fragment 176-191 is under research for its ability to alleviate lipodystrophy. If the postulates are true, it will present an avenue to control abdominal fats and prevent these syndromes. The peptide has shown to have glycemic control properties and it is important to check out the conditions under which fragment 176-191 works best.
Fragment 176-191 and Insulin
There have been many postulations on the effects that fragment 176-191 has on levels of insulin in the system. To understand this, there are three important mechanisms that need explanation. Insulin intolerance studies at the intravenous level and modulation of insulin depended glycogen phosphorylase, modulation of glycogen synthase on the adipose and muscle tissue and how insulin binds to the plasma membrane.
Findings from the research showed that the hexapeptide allows minimum activity of the sequence and it is important in insulin potentiating activities of the peptide which are designed to bind to specific receptors. The system allows the body to modulate numerous functions of the phosphorylase and synthase enzymes. This in turn increases the storage of glycogen in the adipose tissue, liver and liver cells.
Fragment 176-191 and Hyperglycemia
There are numerous synthetic peptides in the market and they are synthetically designed in correspondence with the amino acids. Like the unmodified growth hormone, the fragment is important in preventing the deposition of fats on peripheral and visceral organs.
In addition, fragment 176-191 is essential in the formation of lipids and fats breakdown. The recommended dosage of the peptide during research is typically 500 mcg to 1000 mcg. The peptide can be split into different doses depending on the day.
Research showed that fragment 176-191 has maximum effects on the 4th week since it was administered. It is recommended that the peptide is injected half an hour before feeding the test subject. The hormone stimulates fats breakdown and the increase in glucose concentration. This allows test subjects to consume high calories and do not store fats on peripheral organs.
Fragment 176-191 has several side effects as per research conducted. Side effects may include swelling of limbs, dysphora, lethargy and water retention. However, research showed that the peptide may be released for human consumption once all the required clinical trials and research has been conducted and approved by the relevant food and drug agencies.
Close counterparts of the peptide include 180-191, 176-191 and 178-191. All these showed the ability to induce a high insulin production while sustaining the level for a long time. This allowed the peptide to travel throughout the body to find the exact and functional receptor.
Further studies are being conducted to find the peptides ability to present it in the most natural and effective form that can be active without affecting concentration or effectiveness of the peptide. Allowing synthetic versions without any adverse side effects on the natural system is the current trend in research and peptide science.
Fragment 176-191 is a PGP9.5 synthetic peptide that corresponds to the amino acids 175-191 PGP9.5. The peptide is also commonly referred to as neuron cytoplasmic protein 9.5 and gracile axonal dystrophy. The concentration that is suggested to be used as antigen or antibody binder in animal species.
When fragment 176-191 is used with antibodies, it must be pre–incubated first before incorporating to any tissue. This is important because it ensures that the amino acids in the peptide are in their active configuration and the binding to the receptors will be exceptional. The structure and configuration of fragment 176-191 play a crucial role in determining its efficacy and potency.